Pfizer Renews Partnership for Next-Gen Approach to Autoimmune Disease
Imcyse for a rheumatoid arthritis program, which is based on that company’s Imotope technology. Pfizer will lead clinical development of the RA program. This is not the first rheumatoid arthritis deal Pfizer and Imcyse have conducted. In 2018, the companies entered into an agreement to develop an Imotope, which is a specific modified peptide that targets rheumatoid arthritis. The Imcyse Imotope platform represents what the companies believe is a next generation and potentially curative approach to severe autoimmune diseases. Imotopes are designed to induce cytolytic T cells, which specifi...
Source: biospace.com